Cadrenal Therapeutics, Inc. Common Stock
General ticker "CVKD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $15.7M (TTM average)
Cadrenal Therapeutics, Inc. Common Stock does not follow the US Stock Market performance with the rate: -21.9%.
Estimated limits based on current volatility of 12.3%: low 6.76$, high 8.65$
Factors to consider:
- Total employees count: 3 as of 2022
- Current price 11.0% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.99$, 27.11$]
- 2025-12-31 to 2026-12-31 estimated range: [4.38$, 16.19$]
Financial Metrics affecting the CVKD estimates:
- Negative: with PPE of -1.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -40.53 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 73.49 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CVKD quotes
Long-term CVKD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $2.70MM | $7.63MM | $10.96MM |
| Operating Income | $-2.70MM | $-7.63MM | $-10.96MM |
| Non-Operating Income | $-4.01MM | $-0.72MM | $0.31MM |
| Interest Expense | $0.11MM | $0.02MM | $0.00MM |
| R&D Expense | $0.39MM | $4.08MM | $4.21MM |
| Income(Loss) | $-6.71MM | $-8.36MM | $-10.65MM |
| Profit(Loss)* | $-6.71MM | $-8.36MM | $-10.65MM |
| Stockholders Equity | $-5.55MM | $7.69MM | $7.44MM |
| Assets | $0.78MM | $8.52MM | $10.12MM |
| Operating Cash Flow | $-1.20MM | $-3.53MM | $-7.36MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.01MM |
| Investing Cash Flow | $-0.00MM | $-0.00MM | $-0.01MM |
| Financing Cash Flow | $1.24MM | $11.90MM | $8.98MM |
| Earnings Per Share** | $-8.66 | $-9.63 | $-8.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.